Managed Care Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
London School of Hygiene & Tropical Medicine
Economic analysis of pneumococcal vaccine for elderly reported
August 16th, 2005
Researchers present an economic analysis of a pneumococcal vaccine program in people aged over 64 years in a developed country setting in a recent issue of the International Journal of Epidemiology. "Polysaccharide pneumococcal vaccination for older adults is being introduced in developed country settings. Evidence of protection by this vaccine against pneumococcal pneumonia, or confirmation that illness and death from bacteremia are prevented, is currently limited. Decisions are often made based on partial information," scientists in England and Gambia report. "We examined the policy implications by exploring the potential economic benefit to...
Source: Managed Care Business Week (2005-08-16)
|
